• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 7, 2018

View Archived Issues

Clinical data for Aug. 6, 2018

Read More

Other news to note

Ascletis Pharma Inc., of Hangzhou, China, said ravidasvir is recommended by the World Health Organization's guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus (HCV) infection as a future pan-genotypic direct-acting antiviral agent. Read More

Earnings

Ironwood Pharmaceuticals Inc., of Cambridge, Mass., reported second-quarter U.S. net sales of Linzess, as reported by its U.S. collaboration partner, Dublin-based Allergan plc, totaling $192 million, a 14 percent increase compared to the second quarter of 2017. Read More

Financings

Kedalion Therapeutics Inc., of Menlo Park, Calif., said it completed a $5 million series A financing led by Lagunita Biosciences. Proceeds will be used to further develop the company's Acustream technology platform through to pilot-scale GMP manufacturing and support advancement of clinical programs. Read More

Qihan sees potential in xenotransplantation, raises $7.8M in series A financing

HONG KONG – China's Hangzhou Qihan Bio Inc. has completed a series A financing to raise $7.8 million for the development of xenotransplantation procedures, engineering pig organs to be transplanted into humans. Read More

Drugging microbiome tackles 'keystone player in cardiometabolic disease'

Scientists at the Cleveland Clinic Foundation have developed small-molecule inhibitors that inhibited the bacterial enzyme chain responsible for processing choline into trimethylamine-N-oxide (TMAO). Read More

BI inks deals with CFGTC, Oxford Biomedica, makes move into gene therapy

LONDON – Boehringer Ingelheim GmbH (BI) is making its first move into gene therapy via an agreement with a U.K. academic group that has been working since 2001 to develop an inhaled gene therapy for cystic fibrosis. Read More

Paratek heads into the last lap with its next-generation antibiotic

Paratek Pharmaceuticals Inc. has one hurdle left before its lead candidate, omadacycline, enters the home stretch of getting FDA approval – Wednesday's half-day session with the Antimicrobial Drugs Advisory Committee. Read More

Rome if you want to: Ovid phase II data in AS garner mixed chorus, some doubt

Not all investors caught the drift of Ovid Therapeutics Inc.'s phase II data with OV-101 (gaboxadol) in Angelman syndrome (AS), but CEO Jeremy Levin told BioWorld that insiders rejoiced and the company is moving ahead with the delta-selective GABAA receptor agonist. Read More

Samumed raises $438M in equity round

Samumed LLC, a small company developing drugs to harness the Wnt pathway to treat multiple conditions, has closed a $438 million equity round at what it said was a pre-money valuation of $12 billion, marking one of the biggest disclosed private company financings of the year to date. Read More

Regeneron, Bluebird 'all in' on cancer cell therapies in five-year pact

"What you have in this collaboration is two very like-minded, scientifically driven organizations that are coming together to bring very synergistic and complementary technologies to the field of CAR T cells and T-cell-based immunotherapy," said Philip Gregory, chief scientific officer of Bluebird Bio Inc., describing a five-year pact with Regeneron Pharmaceuticals Inc. to discover, develop and commercialize cancer cell therapies. Read More

Regulatory actions for Aug. 6, 2018

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe